News

conference

Nov 18, 2020

2020 - CTOS - Clinical Poster

First-in-human Phase I Study of SQ3370, a Click Activated Protodrug Therapy, in Patients with Soft Tissue Sarcomas and Other Advanced Solid Tumors

conference

Nov 18, 2020

2020 - CTOS - Preclinical Poster

SQ3370 Activates Cytotoxic Drugs at Tumor via Click Chemistry and Produces Sustained Responses in Injected and Non-injected Lesions in Preclinical Models

press

Nov 12, 2020

Press Release

Shasqi presents Trial-in-Progress and preclinical posters at SITC 2020

conference

Nov 9, 2020

2020 - SITC - Clinical poster

First-in-human Phase I Study of SQ3370, a Click Activated Protodrug Therapy, in Patients with Advanced Solid Tumors

media

Oct 28, 2020

Science.org

Click Chemotherapy

media

Oct 23, 2020

C&EN

Click chemistry sees first use in humans

press

Oct 14, 2020

Press Release

Shasqi Announces Click Chemistry Breakthrough with First-Ever Human Application in Launch of Clinical Program

media

Oct 14, 2020

Forbes

Side Effects From Chemo Can Be Devastating. This Startup Aims To Change That.

conference

Oct 9, 2020

2020 - MSTS - Preclinical Abstract

SQ3370, a Novel Technology to Locally Capture and Activate Cytotoxic Drugs, Produces Systemic Responses in Injected and Non-injected Lesions via Immune Activation

press

Jun 22, 2020

Press Release

Shasqi Demonstrates Chemistry-based Platform Produces Local and Systemic Anti-tumor Response in Preclinical Cancer Model

conference

May 29, 2020

2020 - ASCO

Local Activation via SQ3370 Enhances the Safety of Chemotherapy with Concomitant Antitumor Immune Response

conference

Apr 24, 2020

2020 - AACR

SQ3370, a Local Activation Therapy of Cytotoxic Agents, Produces Sustained Responses in Target and Distal Lesions via Immune Activation